<DOC>
	<DOCNO>NCT01183676</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's divalproex sodium-delayed-release tablet 500 mg tablet Abbott 's DepakoteÂ® 500 mg tablet follow single , oral 500 mg ( 1 x 500 mg ) dose administration feed condition .</brief_summary>
	<brief_title>Fed Bioequivalence Study Divalproex Sodium Delayed-Release Tablets , 500 mg</brief_title>
	<detailed_description />
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Females child bear potential male . No hormonal contraceptive hormonal replacement therapy permit study . Women consider childbearing potential one follow report documented medical history : postmenopausal spontaneous amenorrhea least one ( 1 ) year , spontaneous amenorrhea le one ( 1 ) year serum FSH level &gt; 40 mIU/ml , bilateral oophorectomy without hysterectomy absence bleed least 6 month , total hysterectomy absence bleed least 3 month . During course study , study screen study exit include washout period , men must use spermicide contain barrier method contraception addition current contraceptive method . These instruction document informed consent form . 3 . Weight Restrictions : At least 60 kg ( 132 lb ) men At least 48 kg ( 106 lb ) woman All subject Body Mass Index ( BMI ) less equal 30 great equal 19 ( see Part II , Administrative Aspects Bioequivalence Protocols ) . BMI value round nearest integer ( ex . 30.4 round 30 , 18.5 round 19 ) 4 . All subject judge principal subinvestigator physician list Form FDA 1572 normal healthy prestudy medical evaluation perform within 21 day initial dose study medication include : 5 . Normal nonclinically significant physical examination include vital sign , 6 . Within normal limit nonclinically significant laboratory evaluation result follow test : Serum Chemistries : sodium , potassium , chloride , BUN , iron , albumin , total protein AST , Alk . Phos. , Calcium , Creatinine , ALT , Total bilirubin , Total Cholesterol , Phosphate , Uric Acid , Nonfasting Glucose Triglycerides Hematology : Platelet Count , Hemoglobin , Leukocyte Differential , Hematocrit , Red Blood Cells Urinalysis : Appearance , Specific Gravity , Protein pH , Microscopic Examination 7 . Negative Hepatitis B Hepatitis C test , 8 . Negative HIV test , 9 . Normal nonclinically significant 12lead ECG 10 . Negative urine drug screen follow compound : amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , methadone , opiates , phencyclidine 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobaccocontaining product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . Individual history drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within fourteen ( 14 ) day prior initial dose study medication . 2 . Use hormone replacement therapy within 3 month prior study medication dosing . 3 . Use medication know induce inhibit hepatic enzyme activity within 28 day prior initial dose study medication ( see Part II , Administrative Aspects Bioequivalence Protocols list ) . 4 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , congenital metabolic disorder neurologic disease . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . All laboratory value reflect hepatic function must 10 % upper range normal order consider clinically significant . 5 . Subjects know urea cycle disorder group uncommon genetic abnormality ( e.g . ornithine transcarbamylase deficiency ) . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity Divalproex Sodium related product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>